An albumin-recruiting lipid nanoparticle formulation promotes lymphatic drainage while avoiding liver accumulation. In preclinical models of cancers and infectious diseases, mRNA vaccines prepared from this lipid nanoparticle platform elicit robust immune responses and achieve remarkable efficacy.